Castle Biosciences Inc

CSTL remains in a Stage 2 Advancing corrective reset with an active Lockout Rally driving upside urgency. The medium-term bias is bullish, supported by a clear HH/HL sequence and price holding above rising 9/20 EMAs. Despite overbought conditions, the Lockout Rally override justifies immediate participation. Optimal entries target shallow pullbacks into the 9/20 EMA zone. Key risks include failure to hold EMA support, a decisive break below the 50DMA, or rejection at the overhead 200DMA.

• ↑Q1 2026 revenue reached $83.7 M, rising 42% YoY
• ↑DecisionDx melanoma and TissueCypher test volumes grew 36% YoY
• ↓Q1 2026 net loss was $14.5 M; adjusted gross margin down to 75.6%